Residual Mitral Regurgitation After Transcatheter Aortic Valve Replacement: An Important Target for Intervention
Journal of the American Heart Association · 2023
DOI: 10.1161/jaha.123.031400 ↗Kurz gefasst
Editorial in der Zeitschrift Journal of the American Heart Association, 2023. Verfasst von Grant W Reed und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute Cleveland Clinic Cleveland OH USA. Hauptthemen laut MEDLINE: Transcatheter Aortic Valve Replacement, Mitral Valve Insufficiency, Aortic Valve Stenosis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
rincipal to optimizing outcomes after transcatheter aortic valve replacement (TAVR) is understanding each patient’s individualized procedural risks and taking steps to maximize their likelihood of a good long-term result in the years after treatment. This includes appropriate patient selection, proper valve choice, implantation strategies to minimize pacemaker dependency and maximize the success of future valve- in-valve procedures if needed, and often how to co-manage significant concomitant valve disease. Patients with low-flow, low-gradient (LFLG) severe aortic valve stenosis (AS) represent a particularly high-risk patient group, because they either have significant left ventricular (LV) systolic or diastolic dysfunction that impairs stroke volume, as well as a fixed outflow obstruction from AS, all of which combine to negatively affect prognosis. Mitral regurgitation (MR) is especially prevalent in LFLG severe AS; it is seen in upwards of one-third of patients 1– 3 and portends worse outcomes, 2 yet data to guide the management of patients with LFLG severe AS and at least moderate MR are scarce. A heart team approach is particularly important in these patients, as management strategies can be complex, ranging from surgical AVR+surgical mitral valve repair or mitral valve replacement in appropriate surgical candidates, TAVR with plans for transcatheter edge- to-edge mitral valve repair (TEER) or transcatheter mitral valve replacement staged at a later date, or medical management of MR in patients not TEER or transcatheter mitral valve replacement candidates or whose MR improves after TAVR
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute Cleveland Clinic Cleveland OH USA.
ORCID-Profile: Grant W Reed, Samir R Kapadia
Zitieren
APA
Reed, G. W., & Kapadia, S. R. (2023). Residual Mitral Regurgitation After Transcatheter Aortic Valve Replacement: An Important Target for Intervention. Journal of the American Heart Association. https://doi.org/10.1161/jaha.123.031400
Vancouver
Reed GW, Kapadia SR. Residual Mitral Regurgitation After Transcatheter Aortic Valve Replacement: An Important Target for Intervention. Journal of the American Heart Association. 2023. doi:10.1161/jaha.123.031400
BibTeX
@article{Reed2023,
author = {Reed, Grant W and Kapadia, Samir R},
title = {Residual Mitral Regurgitation After Transcatheter Aortic Valve Replacement: An Important Target for Intervention},
journal = {Journal of the American Heart Association},
year = {2023},
doi = {10.1161/jaha.123.031400}
}
EUVIMED